Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hisamitsu Pharmaceutical Co ( (JP:4530) ) just unveiled an update.
Hisamitsu Pharmaceutical has revised its dividend forecast for the fiscal year ending February 28, 2026, deciding that no year-end dividend will be paid, conditional on the successful completion of a tender offer by Taiyo Kosan to acquire its common stock, share acquisition rights and American Depositary Receipts. The board has expressed support for the tender offer, recommended that shareholders participate, and acknowledged that the offer price was set on the basis that no year-end dividend would be paid, paving the way for a planned privatization and eventual delisting of the company’s shares, which will materially affect shareholder returns and the company’s status as a public company.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen4677.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Ltd. is a Japanese drugmaker known for developing and manufacturing pharmaceutical products, with a history of providing stable shareholder returns through dividends. The company is listed in Japan and its shares are also represented overseas via American Depositary Receipts.
Average Trading Volume: 183,552
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen328.3B
See more insights into 4530 stock on TipRanks’ Stock Analysis page.